REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Apoptotic Extracellular Vesicles: Emerging Biomarkers for Cancer and Neurodegenerative Disease Diagnostics
Provisionally accepted
- University of Milan, Milan, Italy
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
A new subclass of extracellular vesicles formed on terminal apoptosis, apoptotic extracellular vesicles (ApoEVs), has been found to be potential markers for disease diagnosis, prognosis, and monitoring of treatment. Highlighting their role in neurological disorders and cancer as diagnostic markers, this review aims to present a new paradigm of ApoEV classification based on their biogenic process, cargo composition, and functional attributes. The heterogenous molecular content of such membrane-bound vesicles-like proteins, lipids, DNA, and RNA pro-duces unique fingerprints reflective of the pathologic and physiological status of their parent cells. We critically examine the clinical significance, specificity, and sensitivity of current technological advancements in identifying and fractionating ApoEV through methodologies like flow cytometry, imaging processes, and molecular analysis. The prognostic and diagnostic potential of ApoEVs in cancer and neurological disease is the specific focus of this review. We address conflicting evidence, discuss controversy in the field, and contrast ApoEV-based methods with traditional biomarkers. We discuss the challenges of isolating, detecting, and validating ApoEVs and provide a standardized diagnostic procedure for clinical application. Lastly, we outline the next-generation research directions such as AI-assisted ApoEV analysis, emerging biosensor technologies, and ApoEV platforms for the specific purpose of application in personalized medicine. Finally, this thorough review critically evaluates the biological and technical hurdles which should be addressed for successful clinical translation, and the untapped potential of ApoEVs as non-invasive diagnostics.
Keywords: apoptotic extracellular vesicles, Apoptotic bodies, Cancer diagnostics, Neurodegenerative Diseases, Isolation techniques, biomarkers, clinical translation, standardization
Received: 28 Apr 2025; Accepted: 05 Nov 2025.
Copyright: © 2025 Soleymaninejadian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ehsan Soleymaninejadian, ehsan.soleymaninejadian@unimi.it
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.